amodiaquine-artesunate (AQAS) fixed-dose
DrugOther names: coarsucam, winthrop, co-formulated
NCT Number: NCT01967472
The aim of this study is to address this gap in knowledge by measuring the level of patient adherence to co-formulated amodiaquine and artesunate (AQ-AS) compared to artemether-lumefantrine (AL) under routine conditions in Sierra Leone and explore the key factors that influence adherence. This will be addressed through a mixed methods study that will provide not only a measurement of adherence ACTs and malaria test results, but will also provide contextual information in order to better understand factors that affect adherence. Data will be collected through a series of interviews with health workers and parents/caregivers and through observations of patient-provider consultations.
The first stage of the study begins with semi-structured interviews and observations of patients/caretakers' consultations with health workers and will look at how health workers diagnose and treat malaria. This will be followed by short exit interviews at the health facility with caregivers to assess patient satisfaction with services, as well as to test the consistency between the data obtained through structured observations and the exit interviews.
Follow-up surveys at the homes of patients will be used to measure and compare the adherence of participants to two different ACTs (AQAS and AL) formulations and potential factors that affect adherence. Additionally, data will be collected using in-depth interviews to collect supplementary information in order to discover, in more detail, factors that may affect behavioral choices and/or attitudes with regard to adherence.
Looking for future studies?
Notify Me6 month–59 month
All sexes
Interventional
Not applicable
George Brook Health Center, Freetown, Sierra Leone
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
-
Other names: coarsucam, winthrop, co-formulated
Other names: coartem, AL, locally all Artemether-lumefantrine called 'lokmal'
Time frame: Day 4
Adherence is measured on the day following the last day of treatment. Adherence is defined as taking all of the prescribed dose at the correct time.
London School of Hygiene and Tropical Medicine
Other
Adherence to Artemisinin-Based Combination Therapy (ACT) for the Treatment of Malaria in Sierra Leone
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05978037
Infections, Malaria
Oxford, Oxfordshire, United Kingdom
View Trial DetailsNCT05891236
Infections, Malaria
Baltimore, Maryland, United States
View Trial DetailsNCT07060508
Infections, Malaria
Faladié, Koulikoro, Mali
View Trial DetailsNCT04529434
Diarrhoea;Acute, Infections
Dar Es Salaam, Mtwara, Tanzania
View Trial Details